Company Overview

10x Genomics, Inc. is a U.S.-based life sciences technology company focused on developing genomic analysis tools that enable researchers to study biology at high resolution and scale. The company operates primarily in the biotechnology, life sciences research, and genomics industries, with products designed for applications in single-cell analysis, spatial biology, and immune profiling. Its technologies are widely used by academic institutions, biopharmaceutical companies, and translational research organizations for research into cancer, immunology, neuroscience, infectious disease, and cell and gene therapy development.

The company’s principal revenue drivers include sales of instruments, consumables, and software associated with its genomics platforms, particularly the Chromium and Visium product families. Consumables represent a significant recurring revenue component due to repeat usage in research workflows. Founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness, 10x Genomics evolved from a focus on microfluidics-enabled single-cell sequencing into a broader spatial and multiomics platform company. The company has positioned itself as a leader in high-throughput single-cell genomics through proprietary barcoding, partitioning, and spatial transcriptomics technologies that support large-scale biological analysis.

Business Operations

10x Genomics organizes its business primarily around genomic analysis platforms and associated consumables and software ecosystems. Its core operating areas include Single Cell Gene Expression, Single Cell Immune Profiling, Spatial Gene Expression, and legacy products from the acquired ReadCoor and Cartana businesses that contributed to spatial biology capabilities. Revenue is generated through instrument sales, consumable reagent kits, software licenses, and service-related offerings. Consumables have historically accounted for the majority of total revenue due to recurring customer usage patterns tied to ongoing research activity.

The company operates internationally across North America, Europe, and Asia-Pacific through direct sales organizations and distribution partnerships. 10x Genomics controls proprietary microfluidics and molecular indexing technologies underlying its platforms and maintains a substantial intellectual property portfolio related to single-cell sequencing and spatial analysis. Major subsidiaries include 10x Genomics AB in Sweden, associated with spatial transcriptomics operations. The company has also entered collaborations with pharmaceutical and academic research organizations to expand applications of its platforms in translational medicine and drug discovery.

Strategic Position & Investments

10x Genomics has emphasized long-term growth through continued investment in platform innovation, expansion of spatial biology capabilities, and integration of multiomics workflows. The company has invested heavily in research and development to improve throughput, resolution, and automation for genomic analysis. Strategic priorities have included expanding adoption of spatial transcriptomics technologies and increasing penetration in clinical and translational research markets, although most products remain research-use-only. Management has also focused on strengthening software and bioinformatics capabilities to support increasingly data-intensive genomic workflows.

The company has completed acquisitions to expand its technology portfolio, including ReadCoor and Cartana, which enhanced its spatial genomics offerings and contributed to development of the Xenium in situ platform. 10x Genomics has also invested in intellectual property protection and litigation related to single-cell sequencing technologies, reflecting the competitive importance of proprietary platform architectures within the genomics tools sector. Emerging areas of involvement include spatial multiomics, high-plex tissue imaging, and integrated genomic analysis workflows designed to support precision medicine research.

Geographic Footprint

10x Genomics is headquartered in Pleasanton, California, and maintains operations across multiple global regions, including North America, Europe, and Asia-Pacific. The company serves customers in more than 65 countries through a combination of direct commercial operations and third-party distributors. Significant market activity comes from the United States, which remains the company’s largest revenue contributor, alongside growing research adoption in Europe and China.

Internationally, the company has expanded commercial and research support infrastructure to serve major biotechnology and academic research centers. Its European presence includes operations connected to spatial biology development in Sweden, while Asia-Pacific activities support growing genomics research demand in countries such as China, Japan, Singapore, and South Korea. The company’s technologies are broadly utilized by universities, government research institutes, hospitals, and pharmaceutical companies globally.

Leadership & Governance

10x Genomics was co-founded by Serge Saxonov, Ben Hindson, and Kevin Ness. The company’s leadership has consistently emphasized technological innovation, scientific collaboration, and expansion of high-resolution biology tools for research applications. Strategic messaging from leadership has focused on enabling comprehensive cellular and spatial analysis to accelerate biological discovery and therapeutic development.

Key executives include:

• Serge Saxonov – Co-Founder and Chief Executive Officer
• Adam Taich – Chief Financial Officer
• Benjamin J. Hindson – Co-Founder and Chief Scientific Officer
• James W. Brewington – Chief Commercial Officer
• Michael Schnall-Levin – Senior Vice President, Computational Biology
• Eric S. Whitaker – Chief Legal Officer and Secretary

The company is publicly traded on the NASDAQ under the ticker TXG and operates under governance structures consistent with U.S. public company reporting standards, including disclosures through SEC filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q.